Pfizer's Elrexfio extends disease-free survival in late-stage multiple myeloma study
Updated
Updated · MarketWatch · Apr 29
Pfizer's Elrexfio extends disease-free survival in late-stage multiple myeloma study
11 articles · Updated · MarketWatch · Apr 29
The late-stage trial involved adults with relapsed or refractory multiple myeloma who had received at least one prior treatment.
Elrexfio significantly delayed disease progression compared to a standard drug combination, with a safety profile consistent with earlier results. Overall survival data are not yet mature as the trial continues.
Elrexfio is already approved in the U.S. for heavily pretreated patients, and Pfizer aims to expand its use to earlier treatment lines, supporting broader evaluation in monotherapy and combination regimens.
With severe toxicity warnings, can Elrexfio's benefits outweigh its risks for patients in earlier treatment stages?
Will the final survival data confirm Elrexfio's promise, or is the celebration premature?
This therapy extends life, but will its high price tag create a barrier for the very patients who need it?
As fatal outcomes for this drug class rise, is the push for earlier treatment moving too fast for patient safety?
Pfizer bets its future on cancer drugs. Is this success enough to secure its dominance against looming patent cliffs?